Limb arteriolar vasculitis induced by pembrolizumab plus chemotherapy in a patient with lung cancer.
Immune-related adverse events
Lung cancer
Pembrolizumab
Raynaud’s phenomenon
Vasculitis
Journal
International cancer conference journal
ISSN: 2192-3183
Titre abrégé: Int Cancer Conf J
Pays: Singapore
ID NLM: 101734231
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
10
09
2020
accepted:
12
10
2020
entrez:
25
1
2021
pubmed:
26
1
2021
medline:
26
1
2021
Statut:
epublish
Résumé
Immune-related adverse events (irAEs) associated with immune checkpoint inhibitors are becoming more common; however, irAEs involving blood vessels are rare. We report a patient with limb arteriolar vasculitis induced by pembrolizumab plus chemotherapy. He was 60-year-old man who received first-line treatment with pembrolizumab plus chemotherapy for postoperative lung cancer recurrence. Two weeks after the first administration, he experienced Raynaud's phenomenon. We initiated a vasodilator, but his symptoms worsened, and we considered an irAE. We initiated oral prednisolone, and his symptoms gradually improved. A few weeks later, we performed skin biopsies of both of the patient's feet, and pathological examination revealed arteriolar thrombosis with slight perivascular lymphocytic infiltration. Infiltration of neutrophils with karyorrhexis in the subendothelium was also seen. He also developed acute kidney injury, likely owing to thrombosis. Physical examination of bilateral fingers and toes in patients with lung cancer should be performed carefully after administering pembrolizumab therapy.
Identifiants
pubmed: 33489708
doi: 10.1007/s13691-020-00454-y
pii: 454
pmc: PMC7797381
doi:
Types de publication
Journal Article
Langues
eng
Pagination
83-86Informations de copyright
© The Japan Society of Clinical Oncology 2020.
Déclaration de conflit d'intérêts
Conflict of interestThe authors declare that they have no conflict of interest.
Références
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658
Lancet. 2016 Apr 30;387(10030):1837-46
pubmed: 26970723
J Immunother Cancer. 2018 Feb 12;6(1):12
pubmed: 29433584
Am J Physiol Heart Circ Physiol. 2017 May 1;312(5):H1052-H1059
pubmed: 28314758
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Oncologist. 2020 May;25(5):e753-e757
pubmed: 32167195
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Oncologist. 2017 Jan;22(1):70-80
pubmed: 27534573
Ann Oncol. 2010 Aug;21(8):1712-1717
pubmed: 20147741